An FDA-cleared AI tool for breast ultrasound may reduce unnecessary biopsies of benign breast lesions by about 60%.
Key Details
- 1Research presented at RSNA 2025 evaluated the Koios DS AI tool for breast ultrasound.
- 2The study involved 14 breast imaging radiologists and 271 lesions in 253 women, with 76.8% benign and 23.2% malignant lesions.
- 3The AI tool showed 60.6% specificity, assigning many benign lesions to lower BI-RADS categories, and a sensitivity of 90.5%.
- 4The tool misclassified 6 malignant lesions, most of which had other imaging correlates.
- 5Experts emphasized the AI should be used as an adjunct, not a replacement, to radiologist judgment for biopsy decisions.
Why It Matters
Reducing unnecessary biopsies can lower patient anxiety, cut healthcare costs, and ease operational burdens on imaging practices. Integrating AI as a decision-support tool alongside radiologists could lead to more accurate, efficient, and patient-centered breast imaging workflows.
Source
AuntMinnie
Related News
•AuntMinnie
AI Model Uses Ultrasound to Assess Fetal Lung Maturity
Researchers demonstrated an AI model's strong accuracy in measuring fetal lung maturity from ultrasound images.
•AuntMinnie
AI Advances in Ultrasound Highlighted at AIUM 2026 Keynote
AI is increasingly enhancing ultrasound imaging, clinical workflows, and education, though challenges in trust and implementation remain.
•AuntMinnie
AI Advances in Breast Cancer Risk, CEUS Training Updates, and Imaging AI Variability
This week's top radiology news reviews AI advances in breast and lung cancer risk prediction, new CEUS training standards, and prostate screening updates with imaging modalities.